Loading clinical trials...

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee | Clinical Trials | Clareo Health

RECRUITINGPHASE3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

A Phase 3 Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Trial

NCT07153471•Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 74 weeks.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Have a body mass index (BMI) of 27 kilograms per square meter (kg/m2) or higher at screening
•Have tried at least once to lose weight through diet but were unsuccessful
•Have osteoarthritis of the knee and at least one of the following conditions:
•* Be over 50 years old
•* Have morning knee stiffness that lasts about 30 minutes
•* Have a crackling or grinding sound or feeling in the knee

Exclusion Criteria

•Have gained or lost more than 11 pounds within 90 days prior to screening
•Have had a surgery for obesity or plan to have one in the next 18 months
•Have an active knee infection
•Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
•Have had a recent heart condition or New York Heart Association Functional Classification Class IV congestive heart failure
•Have used any glucagon-like peptide-1 (GLP-1) receptor agonist medication within 180 days of screening

Locations (94)

Arizona Research Center

Phoenix, Arizona, United States

AMR Clinical

Tempe, Arizona, United States

Care Access - Huntington Beach

Huntington Beach, California, United States

Care Access - Thousand Oaks

Thousand Oaks, California, United States

Legacy Clinical Trials

Colorado Springs, Colorado, United States

Chase Medical Research, LLC

Waterbury, Connecticut, United States

Care Access - Decatur

Decatur, Georgia, United States

North Georgia Clinical Research

Woodstock, Georgia, United States

Northwestern University

Chicago, Illinois, United States

AMR Clinical

Newton, Kansas, United States

Key Dates

Start Date

September 15, 2025

Primary Completion Date

April 1, 2028

Completion Date

May 1, 2028

Last Updated

March 20, 2026

Enrollment

800

ESTIMATED participants

Conditions

Osteoarthritis

Interventions

Orforglipron

DRUG

Placebo

DRUG

Contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

CONTACT

1-317-615-4559 LillyTrials@Lilly.com

Physicians interested in becoming principal investigators please contact

CONTACT

clinical_inquiry_hub@lilly.com

A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis

NCT07351968

Moderate Pain in Knee OsteoarthritisSevere Pain in Knee Osteoarthritis

View study

RECRUITINGNA

General vs Spinal in Total Joint Arthroplasty (TJA)

NCT06747494

Knee OsteoarthritisHip Osteoarthritis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 20, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

Inclusion Criteria

Exclusion Criteria

A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis

General vs Spinal in Total Joint Arthroplasty (TJA)

CBD for Pain Following Orthopedic Shoulder Surgery

PENG Block Variants With Dexamethasone and Dexmedetomidine in Older Adults

A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression

Knee Injections for Obese Patients With Knee Arthritis